| 06.08 22:31 | dpa-AFX: Ligand Pharmaceuticals Inc Q2 Earnings Summary |
| 06.08 22:27 | dpa-AFX: *LIGAND PHARMA Q2 REVENUES AND OTHER INCOME $41.53 MLN VS. $26.37 MLN LAST YEAR |
| 06.08 22:26 | dpa-AFX: *LIGAND PHARMA Q2 LOSS/SHARE $2.88 VS. PROFIT $0.13 YEAR AGO |
| 06.08 22:26 | dpa-AFX: *LIGAND PHARMA Q2 NET LOSS $51.91 MLN VS. PROFIT $2.29 MLN PRIOR YEAR |
| 06.08 20:01 | dpa-AFX: Ligand Pharmaceuticals Q2 24 Earnings Conference Call At 4:30 PM ET |
| 08.07 13:44 | dpa-AFX: Ligand Pharma To Acquire Apeiron Biologics For $100 Mln |
| 08.07 13:03 | dpa-AFX: *LIGAND PHARMA AGREES TO ACQUIRE APEIRON BIOLOGICS AG FOR $100 MLN |
| 27.06 14:42 | dpa-AFX: Ligand Says Its Partner Verona Pharma's Ohtuvayre Approved By FDA For Maintenance Treatment Of COPD |
| 27.06 14:15 | dpa-AFX: *LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF OHTUVAYRE FOR MAINTENANCE TREATMENT OF COPD |
| 18.06 14:19 | dpa-AFX: Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults |
| 18.06 14:05 | dpa-AFX: *LIGAND SAYS MERCK RECEIVES FDA APPROVAL FOR PNEUMOCOCCAL 21-VALENT CONJUGATE VACCINE FOR ADULTS |
| 30.05 11:56 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2024 |
| 07.05 22:06 | dpa-AFX: Ligand Pharmaceuticals Inc Q1 Profit Increases, beats estimates |
| 07.05 22:04 | dpa-AFX: *LIGAND PHARMA Q1 REVENUES $30.98 MLN VS. $43.98 MLN LAST YEAR |
| 07.05 22:04 | dpa-AFX: *LIGAND PHARMA Q1 EPS $4.75 VS. $2.33 YEAR AGO |
| 07.05 22:04 | dpa-AFX: *LIGAND PHARMA Q1 NET INCOME $86.14 MLN VS. $41.95 MLN PRIOR YEAR |
| 07.05 21:02 | dpa-AFX: Ligand Pharmaceuticals Q1 24 Earnings Conference Call At 4:30 PM ET |
| 07.05 15:42 | dpa-AFX: Ligand Enters Into $100 Mln Royalty Financing Agreement With Agenus For BOT/BAL Clinical Dvpt. |
| 07.05 13:35 | dpa-AFX: *LIGAND AND AGENUS ENTER $100 MLN ROYALTY FINANCING AGREEMENT |
| 03.04 15:27 | dpa-AFX: Ligand Pharmaceuticals Announces Launch Of Pelthos; Scott Plesha To Assume Leadership Of Pelthos |
|
|
